Glaucoma laser left 82% of patients medication-free in U.S. trial In a 318-patient U.S. study, 76% achieved at least 20% eye-pressure reduction and average pressure fell 7.4 mmHg. Detailed data will follow.

#BLCO Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

www.stocktitan.net/news/BLCO/bausch-lomb-an...

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 Bausch + Lomb (NYSE: BLCO) will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET to discuss results and provide a business update.Materials will be posted on the Investor Relations website before the call. A replay will be available until March 4, 2026.Date: Wednesday, Feb. 18, 2026Time: 8:00 a.m. ETWebcast: https://www.webcaster5.com/Webcast/Page/2883/53392Participant dial-in (North America): +1 (888) 506-0062Participant dial-in (International): +1 (973) 528-0011Access code: 923960Replay dial-in (North America): +1 (877) 481-4010; Replay passcode: 53392

#BLCO Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

www.stocktitan.net/news/BLCO/bausch-lomb-wi...

#BLCO Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

www.stocktitan.net/news/BLCO/bausch-lomb-to...

LUMIFY's New Preservative-Free Eye Drops Prove Equal Effectiveness in Major Clinical Trial: 1-Minute Results Last 8 Hours Clinical trial validates preservative-free LUMIFY matches original formula's effectiveness for sensitive eyes. 380-patient study confirms 1-minute activation. See full results.

#BLCO Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

www.stocktitan.net/news/BLCO/bausch-lomb-an...

Bausch + Lomb Announces Two Key Investor Events: Q2 Earnings and Strategic Pipeline Review Day Global eye health leader schedules Q2 results and reveals plans for major investor day featuring innovative pipeline updates. Get complete details.

#BLCO Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

www.stocktitan.net/news/BLCO/bausch-lomb-wi...

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering Bausch + Lomb announced the pricing of an upsized €675 million senior secured floating rate notes offering due 2031, increased from the initially planned €600 million. The Notes will be sold at 99.500% of principal value. The company is also seeking to obtain a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and an $800 million revolving credit facility. The proceeds will be used to repay existing revolving credit facility borrowings, refinance term A and B loans due 2027, and cover related expenses. The Notes will be guaranteed by the company and its subsidiary guarantors, secured by first priority liens. Both the Notes offering and new credit facilities are expected to close on June 26, 2025.

#BLCO Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

www.stocktitan.net/news/BLCO/bausch-lomb-an...

Pomerantz Law Firm Probes Bausch + Lomb Investors' Claims Amid Concerns The Pomerantz Law Firm is actively investigating investor claims against Bausch + Lomb Corporation following a series of troubling disclosures.

Pomerantz Law Firm Probes Bausch + Lomb Investors' Claims Amid Concerns #United_States #New_York #Pomerantz_LLP #Bausch_+_Lomb #BLCO

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CYH, #CLSK, #BLCO, #XPEV, #JPM

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CYH 64% OTM
2. #TSLA 53% OTM
3. #CLSK 53% OTM
4. #BLCO 47% OTM
5. #APP 38% OTM

#OptionFlow #OptionsTrading #Trading

Bausch + Lomb Issues Critical Safety Recall for enVista Eye Implants After TASS Reports Medical alert: enVista lens recall follows TASS complications. All affected patients responded well to treatment. See complete product list and healthcare guidance.

#BLCO Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

www.stocktitan.net/news/BLCO/bausch-lomb-an...

Revolutionary FDA-First: Bausch + Lomb's New AI-Powered Lens Transforms Overnight Myopia Treatment Groundbreaking Arise™ system features cloud-based tech and FDA-approved toric design, revolutionizing myopia treatment for 2 billion affected globally. Smart algorithms enable instant fitting.

#BLCO Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States

www.stocktitan.net/news/BLCO/bausch-lomb-la...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance Bausch + Lomb (NYSE/TSX: BLCO) reported Q4 2024 revenue of $1.280 billion, up 9% year-over-year, with an 11% increase on a constant currency basis. The company posted a Q4 GAAP net loss of $3 million.Full-year 2024 revenue reached $4.791 billion, representing a 16% increase, with growth across all segments. Vision Care revenue grew to $2.739 billion (+8%), Surgical revenue reached $843 million (+10%), and Pharmaceuticals revenue increased to $1.209 billion (+45%).For 2025, the company projects revenue between $4.950-$5.050 billion, representing 5.5-7.5% constant currency growth, and Adjusted EBITDA of $900-$950 million. The guidance factors in foreign exchange headwinds of -$100M for revenue and -$20M for Adjusted EBITDA.

#BLCO Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

www.stocktitan.net/news/BLCO/bausch-lomb-an...

Bausch + Lomb Privatization Deal Falls Through: Revenue Growth Still on Track Eye health leader Bausch + Lomb concludes privatization exploration without transaction, reaffirms commitment to separation from Bausch Health amid strong revenue outlook for 2024.

#BLCO Bausch + Lomb Provides Update on Potential Sale

www.stocktitan.net/news/BLCO/bausch-lomb-pr...

Bausch + Lomb Sets Date for Q4 and Full-Year 2024 Financial Results Announcement Global eye health leader Bausch + Lomb will report Q4 and FY2024 earnings on February 19, 2025, followed by a conference call and webcast at 8 a.m. ET.

#BLCO Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

www.stocktitan.net/news/BLCO/bausch-lomb-wi...

Bausch + Lomb Acquires Whitecap Biosciences, Expands Eye Disease Treatment Pipeline Bausch + Lomb strengthens its eye health portfolio by acquiring Whitecap Biosciences, gaining promising Phase 2 glaucoma therapy WB007 and geographic atrophy treatment candidates.

#BLCO Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

www.stocktitan.net/news/BLCO/bausch-lomb-bo...

Bausch + Lomb Explores Potential Sale in Strategic Move Towards Independence Bausch + Lomb confirms it's evaluating strategic options, including a potential sale, to complete separation from Bausch Health. Board authorizes exploration amid market speculation.

#BLCO Bausch + Lomb Responds to Rumors of a Potential Sale

#news #StockMarket #stocks

www.stocktitan.net/news/BLCO/bausch-lomb-re...

#BLCO Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

www.stocktitan.net/news/BLCO/bausch-lomb-re...

News; ( NYSE: #BLCO ) Bausch + Lomb Receives FDA Approval for enVista Envy(TM) Full Range of Vision Intraocular Lens

#StockMarket #News

NEWS: ( NYSE: #BLCO ) (BLCO) Technical Pivots with Risk Controls

#StockMarket #News

News; ( NYSE: #BLCO ) Why Bausch + Lomb Rallied Today

#StockMarket #News